Vaginal bacterium Prevotella timonensis turns protective Langerhans cells into HIV-1 reservoirs for virus dissemination.
Nienke H van TeijlingenLeanne Carijn HelgersRamin Sarrami-ForooshaniEsther M Zijlstra-WillemsJohn L van HammeCelia Seguí PérezMarleen Y van SmoorenburgHanneke BorgdorffJanneke Hhm van de WijgertElisabeth van LeeuwenJoris Am van der PostKarin StrijbisCarla M S RibeiroTeunis B H GeijtenbeekPublished in: The EMBO journal (2022)
Dysbiosis of vaginal microbiota is associated with increased HIV-1 acquisition, but the underlying cellular mechanisms remain unclear. Vaginal Langerhans cells (LCs) protect against mucosal HIV-1 infection via autophagy-mediated degradation of HIV-1. As LCs are in continuous contact with bacterial members of the vaginal microbiome, we investigated the impact of commensal and dysbiosis-associated vaginal (an)aerobic bacterial species on the antiviral function of LCs. Most of the tested bacteria did not affect the HIV-1 restrictive function of LCs. However, Prevotella timonensis induced a vast uptake of HIV-1 by vaginal LCs. Internalized virus remained infectious for days and uptake was unaffected by antiretroviral drugs. P. timonensis-exposed LCs efficiently transmitted HIV-1 to target cells both in vitro and ex vivo. Additionally, P. timonensis exposure enhanced uptake and transmission of the HIV-1 variants that establish infection after sexual transmission, the so-called Transmitted Founder variants. Our findings, therefore, suggest that P. timonensis might set the stage for enhanced HIV-1 susceptibility during vaginal dysbiosis and advocate targeted treatment of P. timonensis during bacterial vaginosis to limit HIV-1 infection.
Keyphrases
- antiretroviral therapy
- hiv positive
- hiv infected
- human immunodeficiency virus
- hiv testing
- hiv aids
- men who have sex with men
- hepatitis c virus
- hiv infected patients
- induced apoptosis
- south africa
- cell cycle arrest
- high resolution
- endoplasmic reticulum stress
- copy number
- dna methylation
- cell death
- drug delivery
- combination therapy
- high intensity
- replacement therapy
- ulcerative colitis
- genetic diversity